US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,365.37

+0.71720.05%

Number of Gainers:8

Number of Losers:12

Number of Flat:- -

PE:- -

High:1,380.29

Open:1,364.76

Low:1,358.78

Close:1,364.65

Loading ...

Pfizer : Bofa Global Research Raises Price Objective to $27 From $26

THOMSON REUTERS

Johnson & Johnson Gets US FDA Approval for Imaavy

MT Newswires Live

Boost Your Portfolio With These 5 Low Price-to-Book Stocks

Ireland's reliance on foreign multinational taxes grew in 2024

Johnson & Johnson Receives FDA Approval for Imaavy™ (Nipocalimab-Aahu), a New Fcrn Blocker Offering Long-Lasting Disease Control in the Broadest Population of People Living With Generalized Myasthenia Gravis (Gmg)

THOMSON REUTERS

BRIEF-Vaxart Completes Enrollment In Phase 1 Trial For Its Norovirus Oral Pill Vaccine Candidate

Johnson & Johnson Receives FDA Approval for Imaavytm (Nipocalimab-Aahu), a New Fcrn Blocker Offering Long-Lasting Disease Control in the Broadest Population of People Living With Generalized Myasthenia Gravis (Gmg)

THOMSON REUTERS

INOVIO to Present at Upcoming Scientific and Investor Conferences

Vaxart Inc - Topline Data From Phase 1 Trial Expected Mid-2025

THOMSON REUTERS

Vaxart Inc - Plans Phase 2 Study for Norovirus Vaccine in Second Half 2025

THOMSON REUTERS

Vaxart Inc - Phase 3 Trial for Norovirus Vaccine Could Begin in 2026

THOMSON REUTERS

Vaxart Completes Enrollment in Phase 1 Trial for Its Norovirus Oral Pill Vaccine Candidate

THOMSON REUTERS

Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate

Viagra and Mounjaro panic-buying could be behind a 200% export surge from Ireland to the U.S.

Stock Market Crash: 3 Absurdly Cheap Stocks to Load Up on for the Long Haul

BUZZ-Street View: Pfizer's quarterly results to set stage for positive year

Pfizer : Citigroup Raises Target Price to $25 From $23

THOMSON REUTERS

Pfizer's Dividend Yield Is 7.5%. Is It Still Safe?

Pfizer : Leerink Partners Cuts Target Price to $26 From $28

THOMSON REUTERS

Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4568/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1365.3625,"timestamp":1746027670288,"preClose":1364.6454,"halted":0,"volume":39745443,"delay":0,"changeRate":0.000526,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":0.717163,"latestTime":"04-30 11:41:10 EDT","open":1364.7573,"high":1380.285,"low":1358.7754,"amount":1619658053.315082,"amplitude":0.015762,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1746043200000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.640146,"peRate":22.008402,"turnoverRate":0.002562,"increases":8,"decrements":12,"flats":0,"marketCap":1127480115960,"floatMarketCap":1107763387335},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1380.285,"amplitude":0.015762,"preClose":1364.6454,"low":1358.7754,"pbRate":"3.640146","latestPrice":1365.3734,"volume":39746110,"delay":0,"open":1364.7573,"prevYearClose":1274.8187,"prevWeekClose":1341.1263,"prevMonthClose":1427.887,"prevQuarterClose":1427.887,"fiveDayClose":1344.1606,"twentyDayClose":1377.6108,"sixtyDayClose":1350.7439,"secType":"PLATE","market":"US","turnoverRate":0.002563,"peRate":22.008402,"marketCap":1127526970008,"floatMarketCap":1107810001479,"timestamp":1746027672354,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":8,"down":12,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2531058451","title":"Pfizer : Bofa Global Research Raises Price Objective to $27 From $26","url":"https://stock-news.laohu8.com/highlight/detail?id=2531058451","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531058451?lang=en_us&edition=fundamental","pubTime":"2025-04-30 21:37","pubTimestamp":1746020230,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nFWN3R82TT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0456855351.SGD","LU0306807586.USD","LU1066051498.USD","LU0985481810.HKD","SG9999011175.SGD","IE00BLSP4452.SGD","BK4585","BK4599","LU1894683264.USD","LU1057294990.SGD","SG9999001176.USD","SGXZ57979304.SGD","IE00BBT3K403.USD","LU1894683348.USD","BK4581","BK4533","BK4534","BK4588","LU0306806265.USD","IE00B19Z3B42.SGD","LU1883839398.USD","SG9999001176.SGD","BK4007","LU0225284248.USD","LU0868494617.USD","IE00B19Z3581.USD","SG9999013999.USD","IE000M9KFDE8.USD","BK4550","IE00BLSP4239.USD","IE0002270589.USD","LU0225771236.USD","LU1066053197.SGD","LU0321505439.SGD","LU0234572021.USD","SG9999002224.SGD","LU0170899867.USD","LU0289739699.SGD","BK4568","SG9999003800.SGD","LU1023059063.AUD","LU0122379950.USD","PFE","BK4592","SG9999002232.USD","LU0321505868.SGD","LU0058720904.USD"],"gpt_icon":0},{"id":"2531053229","title":"Johnson & Johnson Gets US FDA Approval for Imaavy","url":"https://stock-news.laohu8.com/highlight/detail?id=2531053229","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531053229?lang=en_us&edition=fundamental","pubTime":"2025-04-30 21:31","pubTimestamp":1746019875,"startTime":"0","endTime":"0","summary":"Johnson & Johnson  said Wednesday that it has received approval from the US Food and Drug Administration for Imaavy, a treatment for generalized myasthenia gravis.The treatment, also known as nipocalimab-aahu, has the potential to provide lasting disease control in adults and pediatric patients aged 12 and up who test positive for anti-acetylcholine receptor or anti-muscle-specific kinase antibody, the company said.The company said applications for the approval of nipocalimab are being reviewed by regulatory authorities globally.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BLSP4239.USD","LU0289739699.SGD","LU1506573853.SGD","BK4533","BK4532","LU2602419157.SGD","IE0002141913.USD","LU1244550577.SGD","SG9999002232.USD","BK4550","LU1674673691.USD","IE00BJT1NW94.SGD","LU0985320562.USD","LU0058720904.USD","LU0203345920.USD","LU0203347892.USD","LU1057294990.SGD","LU1674673428.USD","BK4568","LU0345770308.USD","IE00BVYPNV92.GBP","IE00BVYPNW00.USD","IE00BJJMRZ35.SGD","LU1244550494.USD","LU2112291526.USD","IE00B2B36J28.USD","LU0345769128.USD","LU0912757837.SGD","JNJ","LU0345770993.USD","SG9999002224.SGD","LU1718418525.SGD","LU2129689514.USD","LU0345769631.USD","IE00B3T34201.USD","LU0792757196.USD","LU1032955483.USD","LU0114720955.EUR","LU0882574055.USD","LU1162221912.USD","LU1935042991.SGD","LU0234572021.USD","LU1023059063.AUD","IE00BDGV0183.EUR","BK4534","BK4007","IE00B3PB1722.GBP","IE00BN8TJ469.HKD","IE0009355771.USD","LU1778281490.HKD"],"gpt_icon":0},{"id":"2531051865","title":"Boost Your Portfolio With These 5 Low Price-to-Book Stocks","url":"https://stock-news.laohu8.com/highlight/detail?id=2531051865","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531051865?lang=en_us&edition=fundamental","pubTime":"2025-04-30 21:08","pubTimestamp":1746018480,"startTime":"0","endTime":"0","summary":"When considering valuation metrics, the price-to-earnings (P/E) ratio has always been the obvious choice as calculations based on earnings are easy and come in handy. However, in the case of companies that are incurring losses or are in an early cycle of development, generating meager or no profits, price-to-sales (P/S) is a good valuation metric to identify cheap stocks.Other than P/E and P/S, the price-to-book ratio  is also an easy-to-use tool for zeroing in on low-priced stocks that have high-growth prospects.The P/B ratio is used to calculate how much an investor needs to pay for each dollar of the book value of a stock. It is calculated by dividing the current closing price of the stock by the latest quarter's book value per share.Now, let us understand the concept of book value.Moreover, the P/B ratio is not without limitations. It is useful for businesses like finance, investments, insurance and banking or manufacturing companies with many liquid/tangible assets on the books. H","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/boost-portfolio-5-low-price-130800068.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0477156797.USD","LU1699723380.USD","LU1894683348.USD","LU0130103400.USD","IE000M9KFDE8.USD","LU2362541273.HKD","LU0306806265.USD","BSBR","LU0321505439.SGD","LU0130518102.USD","LU2362541513.USD","LU1057294990.SGD","LU0225284248.USD","BK4599","BK4566","BK4568","LU0321505868.SGD","LU2362540622.SGD","PFE","SAN","SG9999013999.USD","LU0170899867.USD","MD","BK4196","CNC","LU0234572021.USD","BK4592","BK4106","SG9999002232.USD","LU0868494617.USD","LU1883839398.USD","LU0477156953.USD","LU1989771016.USD","SG9999003800.SGD","BSAC","LU0289739699.SGD","IE0002270589.USD","IE00BLSP4239.USD","LU0058720904.USD","LU0648000940.SGD","LU1291159041.SGD","LU1201861165.SGD","LU1201861249.SGD","IE00B19Z3581.USD","IE0034235188.USD","IE00BLSP4452.SGD","STNE","LU1023059063.AUD","BK4588","LU0456855351.SGD","BK4559"],"gpt_icon":1},{"id":"2531328480","title":"Ireland's reliance on foreign multinational taxes grew in 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2531328480","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531328480?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:42","pubTimestamp":1746016941,"startTime":"0","endTime":"0","summary":"Ireland's reliance on foreign multinational taxes grew in 2024 DUBLIN, April 30 (Reuters) - Foreign multinationals paid a record 88% of all Irish corporate tax last year, with the largest 10 firms acc","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nL1N3R80MT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","IE00BWXC8680.SGD","LU2106854487.HKD","LU0965508806.USD","LU0289961442.SGD","HK0000306701.USD","LU0289739343.SGD","LU2360032135.SGD","MACW.SI","LU0234572021.USD","IE00B2B36J28.USD","IE00BGHQF631.EUR","LU0787776722.HKD","LU1235294995.USD","LU1280957306.USD","LU2505996681.GBP","LU2602419157.SGD","LU0719512351.SGD","LU1868837136.USD","LU1582987597.SGD","BK4550","BK4581","IE00B7KXQ091.USD","LU0957791311.USD","LU1551013425.SGD","LU2552382058.USD","LU0784383803.USD","LU0203347892.USD","LU1917777945.USD","LU1778281490.HKD","LU1815333072.USD","LU2505996509.AUD","BK4501","BK4585","LU2237443465.HKD","LU2054465674.USD","LU1823568750.SGD","JNJ","LU0494093205.USD","LU0082616367.USD","LU0868494617.USD","AAPL","IE00BJT1NW94.SGD","BK4566","LU1732800096.USD","LU2023250330.USD","LU1244550494.USD","LU1815336760.USD","LU2065171311.SGD","LU2168564149.EUR"],"gpt_icon":1},{"id":"2531034920","title":"Johnson & Johnson Receives FDA Approval for Imaavy™ (Nipocalimab-Aahu), a New Fcrn Blocker Offering Long-Lasting Disease Control in the Broadest Population of People Living With Generalized Myasthenia Gravis (Gmg)","url":"https://stock-news.laohu8.com/highlight/detail?id=2531034920","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531034920?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:29","pubTimestamp":1746016154,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nTUA27KHLX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1506573853.SGD","BK4504","LU1066051498.USD","BK4532","LU1261432733.SGD","LU1674673428.USD","IE00BGHQF631.EUR","LU0203347892.USD","LU1066051225.USD","LU0795875086.SGD","LU2347655156.SGD","BK4585","LU1894683264.USD","LU0985320562.USD","LU1585245621.USD","LU2089984988.USD","LU2430703178.SGD","IE00BBT3K403.USD","LU1066051811.HKD","LU1732800096.USD","LU1894683348.USD","IE00B2B36J28.USD","LU2430703095.HKD","BK4534","BK4588","LU1061106388.HKD","LU1732799900.SGD","LU0203345920.USD","JNJ","BK4550","IE00BLSP4239.USD","IE0002270589.USD","IE0009355771.USD","LU1066053197.SGD","LU0234572021.USD","LU1032466523.USD","SG9999002224.SGD","LU0466842654.USD","LU0912757837.SGD","LU1196500208.SGD","LU2133065610.SGD","LU1718418525.SGD","LU1778281490.HKD","LU0114720955.EUR","IE00BSNM7G36.USD","LU1267930813.SGD","BK4568","LU0122379950.USD","IE00BJJMRZ35.SGD","LU0058720904.USD"],"gpt_icon":0},{"id":"2531348900","title":"BRIEF-Vaxart Completes Enrollment In Phase 1 Trial For Its Norovirus Oral Pill Vaccine Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2531348900","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531348900?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:25","pubTimestamp":1746015944,"startTime":"0","endTime":"0","summary":"BRIEF-Vaxart Completes Enrollment In Phase 1 Trial For Its Norovirus Oral Pill Vaccine CandidateApril 30 (Reuters) - Vaxart Inc VXRT.O:VAXART COMPLETES ENROLLMENT IN PHASE 1 TRIAL FOR ITS NOROVIRUS OR","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nTUA4RVKRQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4568","VXRT"],"gpt_icon":0},{"id":"2531203486","title":"Johnson & Johnson Receives FDA Approval for Imaavytm (Nipocalimab-Aahu), a New Fcrn Blocker Offering Long-Lasting Disease Control in the Broadest Population of People Living With Generalized Myasthenia Gravis (Gmg)","url":"https://stock-news.laohu8.com/highlight/detail?id=2531203486","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531203486?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:25","pubTimestamp":1746015907,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nFWN3R82CA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0289739699.SGD","LU2129689605.HKD","IE00B3PB1722.GBP","IE00B7SZLL34.SGD","LU2133065610.SGD","LU1066053197.SGD","LU0098860793.USD","LU2129689514.USD","LU1244550494.USD","LU1430594728.SGD","IE00B4R5TH58.HKD","IE00B2B36J28.USD","IE00BVYPNW00.USD","LU1674673691.USD","LU2505996681.GBP","BK4568","LU1057294990.SGD","LU1244550221.USD","LU2430703095.HKD","LU1032955483.USD","IE00BFTCPJ56.SGD","BK4533","IE00B42XCP33.USD","LU1718418525.SGD","LU2430703251.USD","IE00BGHQF631.EUR","BK4581","LU1059921491.USD","LU0345770308.USD","LU2129689431.USD","IE0009355771.USD","BK4585","LU2430703178.SGD","IE0034235303.USD","IE00BJJMRZ35.SGD","LU2505996509.AUD","LU1732800096.USD","BK4559","LU0792757196.USD","LU1066051498.USD","LU1196500208.SGD","BK4534","LU0985320562.USD","BK4588","IE00BVYPNV92.GBP","BK4550","IE0002141913.USD","LU1674673428.USD","JNJ","LU1929549753.HKD"],"gpt_icon":0},{"id":"2531317950","title":"INOVIO to Present at Upcoming Scientific and Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2531317950","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531317950?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:05","pubTimestamp":1746014700,"startTime":"0","endTime":"0","summary":"PLYMOUTH MEETING, Pa., April 30, 2025 /PRNewswire/ --INOVIO , a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases,today announced that it will be presenting at several upcoming conferences, including a fireside chat at the Citizens JMP Life Sciences Conference in New York. INOVIO will also present for the first time data on the long-term clinical effect of lead candidate INO-3107 at the American Broncho-Esophagological Association  program at the Combined Otolaryngology Spring Meetings , the largest meeting of otolaryngologists in the U.S.European Laryngological Society Annual Congress Date: May 9Oral presentation: DNA immunotherapy, INO-3107, generates targeted immunologic response and results in surgery reduction for 81% of adults with recurrent respiratory papillomatosis in year 1. American Society of Gene and Cell Therapy Date: May 13Poster Abstract Session: Succe","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/inovio-present-upcoming-scientific-investor-120500832.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/inovio-present-upcoming-scientific-investor-120500832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4175","INO","BK4139","COSM","BK4568","BK4583"],"gpt_icon":0},{"id":"2531397900","title":"Vaxart Inc - Topline Data From Phase 1 Trial Expected Mid-2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531397900","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531397900?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:00","pubTimestamp":1746014400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nTUA4RVKRQ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","VXRT","BK4139"],"gpt_icon":0},{"id":"2531335031","title":"Vaxart Inc - Plans Phase 2 Study for Norovirus Vaccine in Second Half 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2531335031","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531335031?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:00","pubTimestamp":1746014400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nTUA4RVKRQ:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4568","VXRT"],"gpt_icon":0},{"id":"2531313820","title":"Vaxart Inc - Phase 3 Trial for Norovirus Vaccine Could Begin in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2531313820","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531313820?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:00","pubTimestamp":1746014400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nTUA4RVKRQ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","VXRT","BK4139"],"gpt_icon":0},{"id":"2531039693","title":"Vaxart Completes Enrollment in Phase 1 Trial for Its Norovirus Oral Pill Vaccine Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2531039693","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531039693?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:00","pubTimestamp":1746014400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nTUA4RVKRQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VXRT","BK4568"],"gpt_icon":0},{"id":"2531032587","title":"Vaxart Completes Enrollment in Phase 1 Trial for its Norovirus Oral Pill Vaccine Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2531032587","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531032587?lang=en_us&edition=fundamental","pubTime":"2025-04-30 20:00","pubTimestamp":1746014400,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., April 30, 2025  -- Vaxart, Inc.  today announced that it completed enrollment of its Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs head-to-head against its first-generation constructs.“Completing enrollment in this trial bring us one step closer in our development of a norovirus vaccine, where there is a significant unmet need,” said Steven Lo, Chief Executive Officer of Vaxart. \"We are excited about the potential of our second-generation oral norovirus vaccine constructs that we believe may be more potent than our first-generation constructs. We look forward to sharing the topline data in mid-2025.”Note Regarding Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vaxart-completes-enrollment-phase-1-120000706.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4568","VXRT","BK4139"],"gpt_icon":0},{"id":"2531805827","title":"Viagra and Mounjaro panic-buying could be behind a 200% export surge from Ireland to the U.S.","url":"https://stock-news.laohu8.com/highlight/detail?id=2531805827","media":"Fortune","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531805827?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:25","pubTimestamp":1746012325,"startTime":"0","endTime":"0","summary":"Ireland’s tranche of American multinationals is likely behind an aggressive surge in exports from the country back to the U.S., as companies like Pfizer and Eli Lilly scrambled to ship their Viagra and Mounjaro  to the States before a tariff onslaught.The Eurozone member’s economy expanded by 3.2% in the first quarter of 2025, according to data released on Tuesday by the Central Statistics Office . Compared with the same quarter in 2024, the Irish economy expanded by 13.3%.It wasn’t Ireland’s homegrown champions driving the country’s impressive Q1 growth. It instead appears to have come from the country’s increasingly precarious multinationals.Earlier in April, the CSO revealed that Ireland’s exports to the U.S. rose by 8.7 billion  in February, or by 210.5%. The overwhelming majority of these exports, around 90%, came from the chemicals sector, which includes pharmaceuticals. Ireland exported a total of $76 billion worth of goods to the U.S. in 2024, leaving it with a 50 billion  surp","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/viagra-mounjaro-panic-buying-could-112525070.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0097036916.USD","LU1023059063.AUD","LU1035775433.USD","LU1267930730.SGD","LU1551013425.SGD","BK4568","LU1066053197.SGD","LU2491050071.SGD","BK4534","LU1232071149.USD","IE00B19Z3581.USD","LU1974910355.USD","LU0471298694.HKD","LU2237438978.USD","LU2468319806.SGD","IE00B1BXHZ80.USD","LU1057294990.SGD","LU1712237335.SGD","LU2602419157.SGD","LU2361044865.SGD","LLY","IE0002141913.USD","IE0004445239.USD","LU2237443978.SGD","BK4516","LU2552382215.SGD","LU2237443549.SGD","LU1280957306.USD","IE00BBT3K403.USD","LU0306806265.USD","LU2471134952.CNY","LU1868836914.USD","LU2357305700.SGD","SG9999017495.SGD","LU1548497426.USD","LU2552382132.HKD","LU2461242641.AUD","LU0354030511.USD","LU2552382058.USD","BK4592","PFE","BK4585","LU0198837287.USD","LU1868837136.USD","SG9999014898.SGD","SGXZ57979304.SGD","LU0820561818.USD","LU1623119135.USD","LU0640476718.USD","LU2471134796.USD"],"gpt_icon":1},{"id":"2531038942","title":"Stock Market Crash: 3 Absurdly Cheap Stocks to Load Up on for the Long Haul","url":"https://stock-news.laohu8.com/highlight/detail?id=2531038942","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531038942?lang=en_us&edition=fundamental","pubTime":"2025-04-30 19:05","pubTimestamp":1746011100,"startTime":"0","endTime":"0","summary":"The markets are down this year amid concerns about the economy and tariffs.Many solid stocks are struggling and could make for excellent buys right now.The stocks listed here are trading at attractive earnings multiples and have promising futures ahead.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/04/30/stock-market-crash-3-absurdly-cheap-stocks-to-load/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU1023059063.AUD","BK4581","BK4568","LU1066053197.SGD","LU0306807586.USD","LU1894683264.USD","BK4554","BK4007","IE00B19Z3581.USD","BK4106","BK4533","LU1894683348.USD","IE00BQXX3D17.EUR","LU0058720904.USD","SG9999001176.USD","LU1057294990.SGD","SG9999003800.SGD","BK4599","IE00B19Z3B42.SGD","PYPL","LU0321505439.SGD","LU1861217088.USD","SG9999001176.SGD","LU0985481810.HKD","BK4524","IE000M9KFDE8.USD","BK4551","IE00BLSP4239.USD","LU0122379950.USD","BK4598","SGXZ57979304.SGD","LU0158827948.USD","LU1883839398.USD","LU0306806265.USD","LU2023251221.USD","LU2089283258.USD","SG9999013999.USD","LU0225284248.USD","LU1066051498.USD","SG9999002224.SGD","LU2360107671.USD","LU0289739699.SGD","LU0234572021.USD","LU2089284900.SGD","BK4585","PFE","LU0170899867.USD","LU0321505868.SGD","LU0456855351.SGD","BK4227"],"gpt_icon":1},{"id":"2531707080","title":"BUZZ-Street View: Pfizer's quarterly results to set stage for positive year","url":"https://stock-news.laohu8.com/highlight/detail?id=2531707080","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531707080?lang=en_us&edition=fundamental","pubTime":"2025-04-30 18:59","pubTimestamp":1746010765,"startTime":"0","endTime":"0","summary":"BUZZ-Street View: Pfizer's quarterly results to set stage for positive year** Pfizer PFE.N said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research operations, as the drugmaker expects to be an \"earnings growth\" story over the next three years** Median PT of brokerages covering the stock is $28 - data compiled by LSEGENCOURAGING COMMENTARY** BMO Capital Markets  says outperformance this quarter  positions Pfizer well for the rest of the year, derisking the company's forecast amid a tumultuous economic backdrop** Jefferies  says PFE reported an ok Q1, adding the company's oncology drugs will start to resonate with investors ** Leerink Partners  says the company had encouraging comments on tariffs, dividend and M&A** J.P.Morgan  believes stronger new launch performance and/or further progress on the drugs in development will be necessary to significantly change the current narrative on the stock, which the brokerage sees as more like","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nL4N3R813G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225771236.USD","IE00B19Z3581.USD","SG9999013999.USD","LU0170899867.USD","LU1066051498.USD","LU0456855351.SGD","SG9999011175.SGD","BK4534","SG9999001176.USD","SG9999002232.USD","SG9999002224.SGD","LU1057294990.SGD","BK4588","LU1023059063.AUD","PFE","IE000M9KFDE8.USD","BK4007","BK4581","IE00BBT3K403.USD","LU0225284248.USD","IE0002270589.USD","SG9999001176.SGD","LU0306806265.USD","LU1894683348.USD","LU0321505439.SGD","LU0122379950.USD","LU0321505868.SGD","BK4568","BK4533","BK4599","LU0234572021.USD","LU1066053197.SGD","IE00BLSP4239.USD","LU0058720904.USD","LU0306807586.USD","LU1894683264.USD","SG9999003800.SGD","BK4592","LU1883839398.USD","BK4585","BK4550","IE00BLSP4452.SGD","SGXZ57979304.SGD","IE00B19Z3B42.SGD","LU0868494617.USD","LU0289739699.SGD","LU0985481810.HKD"],"gpt_icon":1},{"id":"2531084287","title":"Pfizer : Citigroup Raises Target Price to $25 From $23","url":"https://stock-news.laohu8.com/highlight/detail?id=2531084287","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531084287?lang=en_us&edition=fundamental","pubTime":"2025-04-30 18:23","pubTimestamp":1746008602,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nFWN3R81T9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BBT3K403.USD","IE00B19Z3581.USD","LU0225771236.USD","LU0321505439.SGD","SG9999002232.USD","BK4568","BK4581","BK4007","LU1894683264.USD","LU0122379950.USD","LU1883839398.USD","SG9999001176.USD","LU0306807586.USD","SG9999001176.SGD","SGXZ57979304.SGD","BK4534","BK4588","LU0234572021.USD","PFE","BK4550","LU0170899867.USD","SG9999003800.SGD","LU0058720904.USD","LU0289739699.SGD","SG9999013999.USD","IE000M9KFDE8.USD","IE00B19Z3B42.SGD","LU1023059063.AUD","BK4585","SG9999011175.SGD","LU0306806265.USD","LU1066051498.USD","LU1894683348.USD","LU0321505868.SGD","LU0225284248.USD","LU1066053197.SGD","IE00BLSP4239.USD","IE0002270589.USD","SG9999002224.SGD","LU0868494617.USD","BK4599","LU0456855351.SGD","LU0985481810.HKD","LU1057294990.SGD","BK4533","IE00BLSP4452.SGD","BK4592"],"gpt_icon":0},{"id":"2531084511","title":"Pfizer's Dividend Yield Is 7.5%. Is It Still Safe?","url":"https://stock-news.laohu8.com/highlight/detail?id=2531084511","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531084511?lang=en_us&edition=fundamental","pubTime":"2025-04-30 18:15","pubTimestamp":1746008100,"startTime":"0","endTime":"0","summary":"A high dividend yield can be enticing, but it can also raise flags for income investors.Pfizer's falling valuation has pushed its yield up to well over 7%, which warrants a closer look.When a stock yields more than 5%, investors start to become skeptical about whether the payout is indeed safe. While it's tempting to want to believe that it can be safe and that it can be an excellent source of future dividend income, you also don't want to get burned and see that dividend get cut or suspended.Consider pharmaceutical giant Pfizer . Its dividend yield is around 7.5% right now, and if the stock continues to decline, it may not be long before it hits 8%. The big question is whether this is really a steal of a deal and a good buy, or if Pfizer may soon have to reduce its dividend?Pfizer's dividend looks safe right now, and with the stock trading at just 8 times its estimated future earnings, it could prove","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/04/30/pfizers-dividend-yield-is-75-is-it-still-safe/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU0225771236.USD","SG9999013999.USD","LU0170899867.USD","US2Y.BOND","LU1066051498.USD","LU0456855351.SGD","SG9999011175.SGD","BK4534","SG9999001176.USD","SG9999002232.USD","SG9999002224.SGD","LU1057294990.SGD","BK4588","US3Y.BOND","PFE","IE000M9KFDE8.USD","BK4007","BK4581","IE00BBT3K403.USD","LU0225284248.USD","US5Y.BOND","IE0002270589.USD","SG9999001176.SGD","US6M.BOND","LU0306806265.USD","LU1894683348.USD","LU0122379950.USD","BK4568","BK4533","BK4599","LU0234572021.USD","LU1066053197.SGD","US30Y.BOND","IE00BLSP4239.USD","LU0058720904.USD","LU0306807586.USD","LU1894683264.USD","SG9999003800.SGD","BK4592","LU1883839398.USD","BK4550","US12M.BOND","SGXZ57979304.SGD","IE00B19Z3B42.SGD","LU0868494617.USD","LU0289739699.SGD","LU0985481810.HKD","US7Y.BOND","US10Y.BOND"],"gpt_icon":1},{"id":"2531081327","title":"Pfizer : Leerink Partners Cuts Target Price to $26 From $28","url":"https://stock-news.laohu8.com/highlight/detail?id=2531081327","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531081327?lang=en_us&edition=fundamental","pubTime":"2025-04-30 18:04","pubTimestamp":1746007496,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250430:nFWN3R81V2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1894683348.USD","SG9999001176.SGD","IE000M9KFDE8.USD","LU0985481810.HKD","LU0306806265.USD","LU0321505439.SGD","LU1057294990.SGD","LU1066051498.USD","LU0225284248.USD","BK4599","LU0321505868.SGD","BK4568","LU1066053197.SGD","LU1894683264.USD","PFE","SG9999013999.USD","LU0170899867.USD","BK4581","IE00BBT3K403.USD","LU0122379950.USD","LU0234572021.USD","BK4550","BK4534","BK4592","SG9999002232.USD","LU0868494617.USD","LU1883839398.USD","BK4533","SG9999003800.SGD","LU0289739699.SGD","IE0002270589.USD","IE00BLSP4239.USD","LU0058720904.USD","BK4585","LU0306807586.USD","SG9999001176.USD","SGXZ57979304.SGD","IE00B19Z3581.USD","IE00B19Z3B42.SGD","IE00BLSP4452.SGD","SG9999011175.SGD","LU1023059063.AUD","LU0225771236.USD","BK4007","BK4588","SG9999002224.SGD","LU0456855351.SGD"],"gpt_icon":0},{"id":"2531024397","title":"Will Pfizer Will Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback?","url":"https://stock-news.laohu8.com/highlight/detail?id=2531024397","media":"Motley Fool","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531024397?lang=en_us&edition=fundamental","pubTime":"2025-04-30 16:51","pubTimestamp":1746003060,"startTime":"0","endTime":"0","summary":"Altimmune and Viking Therapeutics have promising obesity drugs and could be great acquisition targets for Pfizer.Pfizer should be able to easily fund an acquisition of either small drugmaker.However, Pfizer could hold off on the acquisitions front to see how its obesity drug PF-07976016 fares in clinical testing.The market for obesity drugs presents one of the most lucrative targets for biopharmaceutical companies. Eli Lilly and Novo Nordisk are already raking in billions of dollars in sales with their weight-loss drugs. Other drugmakers are eyeing the market as well.Pfizer  is certainly in that group. However, the company finds itself at a distinct disadvantage after it recently threw in the towel on experimental obesity pill danuglipron because of safety concerns. Could Pfizer solve the issue by acquiring an up-and-coming biotech with a promising obesity drug in clinical development?","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/04/30/will-pfizer-will-acquire-altimmune-or-viking-thera/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU0306807586.USD","BK4592","LU0058720904.USD","LU1894683348.USD","LU0122379950.USD","LU0234572021.USD","LU1066053197.SGD","LU1023059063.AUD","SG9999001176.SGD","SGXZ57979304.SGD","LU1066051498.USD","SG9999002224.SGD","SG9999002232.USD","IE00BLSP4452.SGD","SG9999013999.USD","LU0985481810.HKD","BK4139","LU0225771236.USD","BK4568","VKTX","PFE","BK4581","LU1057294990.SGD","IE0002270589.USD","SG9999001176.USD","BK4585","LU0170899867.USD","IE00BBT3K403.USD","LU1883839398.USD","IE00B19Z3581.USD","BK4007","LU0225284248.USD","LU0289739699.SGD","BK4588","LU0456855351.SGD","IE00B19Z3B42.SGD","LU0868494617.USD","IE00BLSP4239.USD","LU0321505868.SGD","SG9999003800.SGD","LU0321505439.SGD","LU0306806265.USD","SG9999011175.SGD","BK4550","BK4533","LU1894683264.USD","IE000M9KFDE8.USD","BK4534","BK4599"],"gpt_icon":1}],"pageSize":20,"totalPage":16,"pageCount":1,"totalSize":309,"code":"91000000","status":"200"}]}}